Inozyme Pharma Valuation
| INZY Stock | USD 2.81 0.12 4.46% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Inozyme Pharma retains a regular Real Value of $7.35 per share. The prevalent price of the firm is $2.81. Our model calculates the value of Inozyme Pharma from evaluating the firm fundamentals such as Return On Asset of -0.36, return on equity of -0.79, and Shares Owned By Insiders of 0.50 % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Inozyme Pharma's valuation include:
Price Book 2.1804 | Enterprise Value 95.7 M | Enterprise Value Ebitda (4.25) |
Undervalued
Today
Please note that Inozyme Pharma's price fluctuation is slightly risky at this time. Calculation of the real value of Inozyme Pharma is based on 3 months time horizon. Increasing Inozyme Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Inozyme Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inozyme Stock. However, Inozyme Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.81 | Real 7.35 | Target 21.0 | Hype 2.65 | Naive 2.65 |
The intrinsic value of Inozyme Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inozyme Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inozyme Pharma helps investors to forecast how Inozyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inozyme Pharma more accurately as focusing exclusively on Inozyme Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inozyme Pharma's intrinsic value based on its ongoing forecasts of Inozyme Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inozyme Pharma's closest peers.
Inozyme Pharma Cash |
|
Inozyme Valuation Trend
Analysing the historical paterns of Inozyme Pharma's enterprise value and its market capitalization is a good way to estimate and gauge the value of Inozyme Pharma over time and is usually enough for investors to make rational market timing decisions.
Inozyme Pharma Total Value Analysis
Inozyme Pharma is currently forecasted to have valuation of 95.7 M with market capitalization of 180.51 M, debt of 46.59 M, and cash on hands of 151.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Inozyme Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
95.7 M | 180.51 M | 46.59 M | 151.48 M |
Inozyme Pharma Asset Utilization
One of the ways to look at asset utilization of Inozyme is to check how much profit was generated for every dollar of assets it reports. Inozyme Pharma retains a negative application of resources of -0.36 (percent), losing $0.003569 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Inozyme Pharma shows how discouraging it operates for each dollar spent on its resources.Inozyme Pharma Ownership Allocation
Inozyme Pharma has a total of 64.24 Million outstanding shares. The majority of Inozyme Pharma outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Inozyme Pharma to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Inozyme Pharma. Please pay attention to any change in the institutional holdings of Inozyme Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Inozyme Pharma Profitability Analysis
Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0.About Inozyme Pharma Valuation
Our relative valuation model uses a comparative analysis of Inozyme Pharma. We calculate exposure to Inozyme Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inozyme Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.3 M | -1.2 M |
Inozyme Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 51.8 M |
Inozyme Pharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Inozyme Pharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Inozyme we look at many different elements of the entity such as Inozyme's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inozyme Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inozyme Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inozyme Pharma's worth.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.